J. Casal

536 total citations
29 papers, 327 citations indexed

About

J. Casal is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, J. Casal has authored 29 papers receiving a total of 327 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 3 papers in Molecular Biology. Recurrent topics in J. Casal's work include Lung Cancer Treatments and Mutations (16 papers), Lung Cancer Diagnosis and Treatment (12 papers) and Lung Cancer Research Studies (11 papers). J. Casal is often cited by papers focused on Lung Cancer Treatments and Mutations (16 papers), Lung Cancer Diagnosis and Treatment (12 papers) and Lung Cancer Research Studies (11 papers). J. Casal collaborates with scholars based in Spain, Switzerland and Argentina. J. Casal's co-authors include Carlos Grande, Virginia Calvo, Bartomeu Massutí, Amelia Insa, Reyes Bernabé, Javier de Castro, Margarita Amenedo, Rosario García Campelo, J.L. González-Larriba and Manuel Cobo and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

J. Casal

27 papers receiving 323 citations

Peers

J. Casal

ONCOL

PRM

IMMUN

Wan Sun United States

Ryan Geschwindt United States

Xia Zhou China

Sebastien Hazard United States

Daniela Caronia Spain

Joseph Tang United Kingdom

Carlos Linn United States

Minae An South Korea

Gareth Rivalland Australia

Tania Labiano Spain

Wan Sun United States

J. Casal

149 ×0.8

ONCOL

145 ×0.9

PRM

30 ×0.7

IMMUN

39 ×0.9

51 ×1.3

Citations per year, relative to J. Casal J. Casal (= 1×) peers Wan Sun

Countries citing papers authored by J. Casal

Since Specialization

Citations

This map shows the geographic impact of J. Casal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Casal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Casal more than expected).

Fields of papers citing papers by J. Casal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Casal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Casal. The network helps show where J. Casal may publish in the future.

Co-authorship network of co-authors of J. Casal

This figure shows the co-authorship network connecting the top 25 collaborators of J. Casal. A scholar is included among the top collaborators of J. Casal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Casal. J. Casal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Isla, Dolores, J. Casal, Manuel Cobo, et al.. (2023). PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement. Journal of Clinical Medicine. 12(15). 5063–5063. 6 indexed citations

Lázaro, M., Patricia Fernández, Luis León‐Mateos, et al.. (2022). Real-world data with afatinib in Spanish patients with treatment-naïve non-small-cell lung cancer harboring exon 19 deletions in epidermal growth factor receptor (Del19 EGFR): Clinical experience of the Galician Lung Cancer Group. Cancer Treatment and Research Communications. 33. 100646–100646. 2 indexed citations

Nadal, Ernest, J.L. González-Larriba, Alex Martínez‐Martí, et al.. (2022). Nivolumab + chemotherapy versus chemotherapy as neoadjuvant treatment for resectable stage IIIA NSCLC: Primary endpoint results of pathological complete response (pCR) from phase II NADIM II trial.. Journal of Clinical Oncology. 40(16_suppl). 8501–8501. 40 indexed citations

Campelo, Rosario García, Jorge García, M. Lázaro, et al.. (2017). The real-world experience with nivolumab in previously treated patients with advanced non small cell lung cancer (NSCLC): A Galician Lung Cancer Group clinical practice.. Journal of Clinical Oncology. 35(15_suppl). e20564–e20564.

Vázquez‐Estévez, Sergio, J. Casal, Francisco Javier Barón-López, et al.. (2016). EGFR testing and clinical management of advanced NSCLC: a Galician Lung Cancer Group study (GGCP 048-10). Cancer Management and Research. 8. 11–11. 16 indexed citations

Grande, Carlos, Mercedes Salgado, Eugénia Gallardo, et al.. (2015). Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer. Cancer Chemotherapy and Pharmacology. 76(4). 731–737. 6 indexed citations

Salvador, J., Luís Manso, Juan de la Haba-Rodríguez, et al.. (2014). Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Clinical & Translational Oncology. 17(2). 160–166. 10 indexed citations

Vázquez‐Estévez, Sergio, et al.. (2014). Second-line treatment in advanced non-small-cell lung cancer in the epidermal growth factor receptor wild-type population. Anti-Cancer Drugs. 25(4). 368–374.

Juan, Óscar, Sergio Vázquez‐Estévez, J. Casal, et al.. (2014). Full-dose cisplatin and oral vinorelbine concomitant with radiotherapy in unresectable stage III non-small cell lung cancer: a multi-center phase II study.. PubMed. 34(4). 1959–66. 6 indexed citations

10.

Grande, Carlos, Sonia Candamio, María José Villanueva, et al.. (2013). Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer. Journal of Geriatric Oncology. 4(2). 114–121. 11 indexed citations

11.

León‐Mateos, Luis, et al.. (2012). First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients. Expert Opinion on Pharmacotherapy. 13(10). 1389–1396. 8 indexed citations

12.

Vázquez‐Estévez, Sergio, Margarita Amenedo, Luis León‐Mateos, et al.. (2007). Biweekly administration of docetaxel and vinorelbine as second-line chemotherapy for patients with stage IIIB and IV non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group (GGCP 013-02). Anti-Cancer Drugs. 18(10). 1201–1206. 2 indexed citations

13.

Casal, J., et al.. (2007). Labial dystonia after facial and trigeminal neuropathy controlled with a maxillary splint. Movement Disorders. 22(9). 1355–1358. 11 indexed citations

14.

Grande, Carlos, et al.. (2007). Docetaxel-induced interstitial pneumonitis following non-small-cell lung cancer treatment. Clinical & Translational Oncology. 9(9). 578–581. 29 indexed citations

15.

Casal, J., et al.. (2007). Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study. Cancer Chemotherapy and Pharmacology. 60(5). 725–732. 6 indexed citations

16.

Grande, Carlos, et al.. (2005). Interleukin-2 for the treatment of solid tumors other than melanoma and renal cell carcinoma. Anti-Cancer Drugs. 17(1). 1–12. 51 indexed citations

17.

Amenedo, Margarita, et al.. (2005). Biweekly docetaxel and vinorelbine as second-line treatment in advanced (stage IIIB+IV) non-small-cell lung cancer (NSCLC). A phase II study of the Galician Lung Cancer Group. Journal of Clinical Oncology. 23(16_suppl). 7334–7334. 1 indexed citations

18.

Morales, Serafín, Manuel Ramos, Miguel Méndez, et al.. (2003). Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study. Cancer Chemotherapy and Pharmacology. 53(1). 75–81. 19 indexed citations

19.

Casal, J., et al.. (1989). Cálculo y diseño de ciclones. Ingeniería química. 115–124. 4 indexed citations

20.

Planas, Jordi, et al.. (1988). Elementos para un análisis sociológico de la transición a la vida adulta. SHILAP Revista de lepidopterología. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact